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Clinical
Examining outcomes following thrombolysis 
in an increasingly older and dependent stroke 
population
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Introduction 
Functional outcomes and quality of life following acute 
ischaemic stroke (AIS) are significantly improved using 
thrombolytic therapy with intravenous recombinant tissue 
plasminogen activator.1 This is the only licensed medical 
therapy for AIS in adults between the ages of 18 and 79 
within four and a half hours from symptom onset based on 
the UK and European Union license.2,3,4 In patients aged over 
80 years stroke thrombolysis is endorsed up to three hours 
from stroke onset and is supported by research evidence2,3,5 
and registry data,6 but there is less clear endorsement in the 
three to four and a half hour time category for those aged 80 
and higher.1,7,8 A recent meta analysis of trial individual patient 
data lends support for using thrombolysis in all age groups up 
to four and a half hours from symptom onset.9 Outcomes are 
less favourable in older patients following thrombolysis10 with 
an increased risk of a devastating outcome and mortality,11, 
12,13 potentially due to the higher rates of comorbidities and 
stroke severity. In addition to age, pre-stroke dependency is 
an exclusion factor in thrombolysis trials, yet since stroke 
incidence is age dependent, and life expectancy is generally 
increasing in developed countries,14 stroke physicians are 
often faced with thrombolysis treatment decisions in older 
patients, often with frailty and dependency.
The primary aims of this study are to explore whether older 
or dependent patients are increasingly likely to receive 
thrombolysis for AIS, and to examine the effect of age and 
pre-stroke dependency on outcomes in our stroke population.
Methods
Data from 831 patients receiving thrombolysis for AIS in our 
centre between 2009 and 2017 were extracted from the SITS 
(Safe Implementation of Treatments in Stroke) database.15 
The SITS database has been locally approved as an audit for 
the purposes of quality assurance and monitoring of use of 
stroke thrombolysis by the local Caldicott guardian (registered 
with quality improvement department ID 5003). As part of 
clinical audit patient consent is not required for submission 
of anonymised data. We adhered to the NHS Code of Practice 
on Protecting Patient Confi dentiality. The SITS database is a 
world wide resource for participating stroke centres to monitor 
the safety and use of thrombolysis, allowing comparison with 
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Background Thrombolysis for acute ischaemic stroke (AIS) patients aged 
≥80 years is evidence based, although its use in previously dependent 
patients is controversial.
Methods Data from 831 thrombolysed AIS patients in our centre from 
2009–2017 were used to compare demographic trends and outcomes 
(haemorrhage, mortality, three-month independence) in patients aged <80 and ≥80 years 
and with prior dependency. Comparison with UK and world registry data regarding age and 
pre-stroke dependency was made.
Results The percentage of treated patients aged ≥80 years increased year-on-year, doubling 
from 25% to 50% (p<0.01), with increasing average age and pre-stroke dependency in world 
centres. Patients ≥80 years had higher (p<0.001) stroke severity, symptomatic intracerebral 
haemorrhage (5% vs. 1.5%), mortality (35% vs. 13%) and lower three month independent 
survival (24% vs. 60%). Patients with pre-stroke dependency had especially higher three month 
mortality (57–71%, OR 3.75 [95% CI 1.97–7.15]) in both age groups. 
Conclusion Patients aged ≥80 years and with dependency increasingly receive thrombolysis. 
Given poorer outcomes thrombolysis trials are needed in pre-stroke dependent patients.
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national and worldwide practice and outcomes with data on 
over 200,000 treated AIS patients. The stroke unit serves 
a population of 523,000 in the north east of Scotland and 
approximately 700 patients are admitted each year. 
Stroke diagnosis was defi ned as a sudden onset focal defi cit 
of cerebral origin lasting for ≥24 hours, where cranial imaging 
showed either positive evidence of AIS, or was normal and the 
clinical syndrome was most consistent with stroke. Pre-stroke 
functional status was measured by the modifi ed Rankin 
score (mRS); three month post stroke mRS was collected 
by stroke nurses trained in administering mRS by review in 
person or by telephone.  Clinical variables obtained included: 
age, sex, pre-stroke mRS, medications, weight, systolic 
and diastolic blood pressure, National Institutes of Health 
Stroke Scale (NIHSS) score, mRS, glucose, cholesterol, past 
medical history, and timings (including stroke onset, arrival 
in hospital, and IV thrombolysis times). Outcomes included 
NIHSS score at 2 and 24 hours post IV thrombolysis; 24 
hour CT head scan results (current infarct, hyperdense artery 
sign, cerebral oedema, and intracerebral haemorrhage) and 
three month mRS. Symptomatic intracerebral haemorrhage 
(SICH) was defi ned using the ECASS II defi nition (any ICH 
with an increase in NIHSS score of ≥4 from baseline),16 
since there is evidence it is the most appropriate defi nition 
in predicting death and poor outcomes.17 Oxfordshire stroke 
subtype [total, or partial anterior circulation infarct (TACI or 
PACI), posterior circulation infarct (POCI) and lacunar infarct 
(LACI)] are provided from the SITS database derived from 
NIHSS,18 but was not available for individual patient analysis. 
For data trends regarding age and pre-stroke dependency 
of AIS patients from the UK and worldwide from the SITS 
database data from 2018 were included.
Statistical analysis
The data were presented as medians with interquartile ranges 
(IQR), mean values with standard deviations or percentages. 
Missing data points were removed from the denominator when 
calculating percentages. Univariable analysis was carried 
out to compare variables in those aged ≥80 and <80 years 
including demographics, past medical history, medications, 
stroke subtypes and outcomes. Continuous variables were 
analysed using the student’s t-test and dichotomised data 
using the chi-squared test. For all analyses, signifi cance was 
taken as p<0.05. Multivariable logistic regression analysis 
was performed to determine which variables independently 
predicted (i) death and dependency (mRS ≥3) and (ii) 
mortality three months after AIS. Variables were entered into 
the model on the basis of clinical plausibility and previous 
associations: age (<80/≥80), sex, smoking history, pre-stroke 
dependency, pre thrombolysis NIHSS, onset to needle time, 
systolic blood pressure, history of previous stroke or TIA, 
history of hypertension, diabetes, atrial fi brillation [AF], heart 
failure, and prior use of antiplatelets, anticoagulation, and 
antihypertensives, and disappearance of dense artery sign. 
Missing data were assumed to be missing at random and 
imputed using multiple imputation. For the analysis for each 
outcome,20 datasets were imputed using predictive mean 
matching and the results of the logistic regression analyses 
were combined using Rubin’s rules. Statistical analyses were 
performed using Stata version 16. 
Results
831 patients received intravenous thrombolysis for AIS from 
our centre between 2009-2017 from the SITS database, 
excluding duplicates and 29 stroke mimics. Stroke mimic 
patients were younger (median age 61 vs. 75 years, 
p=<0.0001) with milder severity (median baseline NIHSS 
score 6 vs. 11, p=0.04). Data from the SITS database 
demonstrated that the average age of thrombolysed AIS 
patients increased between 2009 and 2018 in our centre 
(mean 69.3 vs 73.4 years comparing 2009-13 with 2014-
18, p<0.01), in the UK (69.2 vs 71.7 years, p<0.0001) 
and worldwide (67.2 vs 68.9 years, p<0.0001, Fig. 1). The 
percentage of thrombolysed AIS patients ≥80 years in our 
centre increased from 25% to 50% between 2009 and 2017 
(p<0.01). There was no increase in the proportion of patients 
with pre-stroke dependency (9.7% from 2009–13 vs. 9.4% 
from 2014–18, p=0.85) in our centre, whereas an increase 
was observed in the UK (6.7% vs. 11.4%, p=0.001) and world 
centres (5.8% vs. 7.2%, p=0.03) registry data. 
Baseline Characteristics
Baseline characteristics, stroke subtype, baseline CT head 
characteristics, observations and outcomes are shown in 
Table 1. Three hundred and seven AIS patients were aged 
≥80 (37%) and 524 aged <80 (63%). The older group (age 
≥80) were more commonly female (58% vs. 39% p<0.0001), 
dependent pre-stroke (18% vs. 4% mRS≥3, p<0.0001), with 
signifi cantly higher rates of comorbidity (e.g. hypertension, 
atrial fibrillation or flutter, congestive heart failure and 
previous TIA or amaurosis fugax, Table 1), more likely to be 
receiving aspirin (38% vs. 27%, p=0.001) or heparin (27% vs. 
6%, p<0.0001) pre-stroke; and less likely to smoke, receive 
insulin or antihypertensive medication. 
Stroke subtype, CT characteristics and timings
On average, the older patients weighed less (p<0.0001), 
had lower cholesterol levels (p=0.0001), with higher systolic 
blood pressure (156 vs. 143 mmHg, p<0.0001), more severe 
strokes (NIHSS score 14 vs. 10, and 56% vs. 36% TACI), 
Figure 1 Mean age of stroke patients treated with thrombolysis 
between 2009–2018 in our centre, United Kingdom (country) and 
world-wide (world). Extracted from the SITS database
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 Age
Variable N missing (%) <80 (n=524) ≥80 (n=307) P value
Demographics
Median age (years, IQR) 0 (0) 69 (60-75) 85 (82-88) <0.0001
Female sex 3 (0) 207 (39%) 177 (58%) <0.0001
Independent pre-stroke (%) 78 (9) 472 (96%) 221 (82%) <0.0001
Past medical history
Hypertension (%) 15 (2) 283 (54%) 196 (65%) 0.003
Diabetes (%) 15 (2) 78 (15%) 58 (19%) 0.11
Hyperlipidaemia (%) 18 (2) 60 (12%) 28 (9%) 0.3
Current smoker (%) 14 (2) 108 (21%) 14 (5%) <0.0001
Previous smoker - stopped before stroke onset (%) 33 (4) 130 (26%) 68 (23%) 0.37
Previous stroke (%) 16 (2) 56 (11%) 42 (14%) 0.18
Previous TIA or amaurosis fugax (%) 36 (4) 46 (9%) 42 (14%) 0.03
Atrial fi brillation or fl utter (%) 15 (2) 99 (19%) 95 (31%) <0.0001
Congestive heart failure (%) 15 (2) 11 (2%) 16 (5%) 0.01
Medications
Aspirin (%) 13 (2) 142 (27%) 115 (38%) 0.001
Warfarin (%) 192 (23) 18 (5%) 11 (5%) 0.91
Heparin/heparinoids (%) 21 (3) 30 (6%) 79 (27%) <0.0001
Clopidogrel (%) 13 (2) 60 (12%) 45 (15%) 0.16
Antihypertensive, oral (%) 14 (2) 233 (45%) 84 (28%) <0.0001
Antihypertensive, IV (%) 29 (3) 4 (1%) 5 (2%) 0.24
Statin (%) 32 (4) 203 (40%) 125 (42%) 0.71
Anti-diabetic, oral (%) 32 (4) 34 (7%) 27 (9%) 0.25
Insulin (%) 32 (4) 21 (4%) 4 (1%) 0.03
Stroke characteristics
TACI N/A 36% 56% 0.005
PACI N/A 40% 36% 0.57
LACI N/A 22% 11% 0.03
POCI N/A 0.8% 0.3% 0.63
Baseline NIHSS (Median, IQR) 18 (2) 10 (5-17) 14 (7-20) <0.0001
Observations
Mean systolic blood pressure (mmHg, SD) 193 (23) 143±23 156±22 <0.0001
Mean diastolic blood pressure (mmHg, SD) 323 (39) 80±4 81±17 0.52
Mean weight (kg, SD) 18 (2) 79±16 68±14 <0.0001
Mean capillary glucose (mmol/l, SD) 50 (6) 7±2.5 7±2.5 0.13
Mean Cholesterol (mmol/l, SD) 279 (34) 4.6±1.2 4.0±1.1 0.0001
Dense artery sign on baseline CT 23 (3) 181 (35%) 69 (24%) 0.0009
Table 1 Baseline characteristics of patients <80 and ≥80 years. Patient demographics, past medical history, medications, stroke 
characteristics, observations, timing, radiology and outcomes are shown
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and less commonly lacunar stroke subtype (11% vs. 22%, 
p=0.03). There was no signifi cant difference in the median 
duration of timing of thrombolysis from symptom onset or 
hospital arrival (Table 1). 
Outcomes and complications
At 24 hours post thrombolysis stroke severity was higher in 
those aged ≥80 compared to <80 years (median NIHSS 9 
vs. 5, p<0.0001, Table 1). Disappearance of a hyperdense 
artery on the 24 hour post thrombolysis CT scan was more 
frequent in the younger group (81/181 [45%] vs. 20/69 
[29%], p=0.023). At three months post stroke, compared 
to patients aged ≥80, those in the <80 age group were 
signifi cantly more likely to be alive and independent (60% 
vs. 27%, odds ratio [OR], 4; 95% CI, 2.9 to 5.4; p<0.0001), or 
have an excellent outcome (disability-free survival, mRS 0-1, 
42% vs. 14% mRS 2-6, OR 4.3 95% CI 3.0-6.4, p<0.0001), 
whereas the ≥80 group had higher three month mortality 
(34% vs. 14%, OR 3.5; 95% CI, 2.4 to 5.0, p<0.0001). 
Of patients independent pre-stroke, those aged ≥80 (i.e. 
mRS ≤2) had three-month mortality rate of 30%, compared to 
4.7% (p<0.001) in those aged <80. For those with pre-stroke 
dependency (mRS ≥3) mortality was 57% in the ≥80 group, 
compared to 71% (10/14, p=0.32) in patients aged <80. 5% 
of those in the older age group developed SICH16 compared 
to 1.5% of those <8 0 (OR 3.8; 95% CI, 1.5 to 9.4; p=0.003). 
Multivariable Analysis
In multivariable analysis, the statistically signifi cant (p<0.05) 
independent predictors of independent survival (three month 
mRS ≤2) were age, pre-stroke mRS, baseline NIHSS score, 
current smoking (compared to never smoking) and congestive 
cardiac failure, whereas for death at three months, the 
signifi cant predictors were identical excluding smoking (Table 
2). Interaction between age category and disappearance of 
the hyperdense artery sign was signifi cant (p=0.02) in the 
model of death or dependency at three months indicating the 
association between good outcome and the disappearance 
of this sign was much stronger in under 80s than over 80s 
(but in the model of death the interaction was nonsignifi cant). 
Interactions between age category and dependency status 
pre-stroke, onset to needle time, NIHSS score, and systolic 
BP were not signifi cant. 
Discussion
This study demonstrates that in our centre, the average age of 
AIS patients treated with thrombolysis is increasing, with more 
than 50% currently treated being ≥80 years old. Additionally, 
in the UK and worldwide contributing stroke centres this 
change is paralleled, with a proportional increase in treated 
patients being dependent pre-stroke. This may be explained 
by the ageing population and, consequently, increasing stroke 
incidence linked to age.14 The positive results from the IST-3 
trial in the over 80s subgroup within three hours of symptom 
onset may have encouraged clinicians to extend the range 
of patients they treat.5 Additionally in 2008, the Scottish 
Intercollegiate Guideline Network recommended treating 
AIS patients with thrombolysis within four and a half hours 
of stroke onset and did not exclude patients aged ≥80.3 
Thrombolysed stroke patients aged ≥80 had more severe 
strokes, with higher rates of pre-stroke dependency and co-
morbidity including AF, in keeping with prior studies.19 
Timings
Median DTN (minutes, IQR) 10 (1) 48 (33-71) 59 (36-70) 0.33
Median symptom onset to thrombolysis (IQR) 20 (2) 145 (107-200) 153 (115-199) 0.43
24 hour cranial CT
Current infarct 41 (5) 385 (75%) 212 (74%) 0.84
Dense artery sign 66 (8) 100 (19%) 49 (17%) 0.41
Any cerebral oedema 41 (5) 138 (27%) 92 (32%) 0.11
Any ICH 34 (4) 51 (10%) 57 (20%) <0.0001
SICH 34 (4) 7 (1.5%) 14 (5%) 0.003
Outcomes
NIHSS at 2 hours (median, IQR) 72 (9) 7 (3-14) 10 (5-18) <0.0001
NIHSS at 24 hours (median, IQR) 88 (10) 5 (2-11) 9 (3-17) <0.0001
3-month independence (mRS≤2, %) 36 (4) 301 (60%) 80 (27%) <0.0001
3-month excellent outcome (mRS≤1, %) 36 (4) 209 (42%) 41 (14%) <0.0001
3-month mortality (mRS=6, %) 36 (4) 73 (14%) 107 (34%) <0.0001
TACI: total anterior circulation infarct; PACI: Partial anterior circulation infarct; LACI: Lacunar infarct; POCI: posterior circulation infarct; 
NIHSS: National Institutes of Health stroke scale; DTN: Door to needle time; SICH: Symptomatic intracerebral haemorrhage (SICH); 
mRS: modified Rankin scale
Table 1 (cont.) Baseline characteristics of patients <80 and ≥80 years
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AF predisposes to higher stroke severity and mortality.20 At 
three months post-stroke patients aged ≥80 compared to <80 
were less likely to retain independence or achieve disability 
free survival. Good outcomes (independent survival, mRS ≤2) 
and mortality at three months were both independently linked 
to age, stroke severity, pre-stroke functional status, cardiac 
failure, disappearance of a hyperdense artery, with current 
smoking a negative predictor of good outcome. Despite 
poorer outcomes in those aged over 80 years, studies 
show the absolute benefit2 and relationship5,6 between 
the administration of thrombolysis and better outcomes 
remains. However, the risks and benefi ts of treatment in older 
patients with pre-stroke dependency may not be as clear, 
and treatment discussions regarding thrombolysis should 
highlight this uncertainty. We found that the disappearance of 
a hyperdense artery sign predicted much lower risk of death 
or dependency in patients <80 but not in patients age ≥80 
years. Persistence and growth of a hyperdense artery sign 
on a CT scan post thrombolysis is linked to age, whereas 
decrease in this sign was more likely with thrombolysis.21 
Disappearance of a hyperdense artery is more likely, the 
shorter its length.22 Therefore older patients with higher 
stroke severity, may have greater clot burden which is more 
resistant to IV thrombolysis, which may be more likely to 
recanalise following endovascular clot retrieval.
Many studies have demonstrated that the risk of SICH post 
thrombolysis is not higher in older patients.23-25 However, 
our study demonstrated a significantly greater rate of 
SICH in patients aged ≥80 in univariate analysis (5% vs. 
1.5%). A possible explanation for this is the higher rates of 
hypertension, and use of aspirin or heparin in those ≥80 
years.9 Also current smoking was lower, stroke severity higher 
and persistence of a hyperdense artery more common in the 
older group, all factors that may make SICH more likely.26,27 
As there were only 21 cases of SICH, we had insuffi cient 
power to perform multivariate analysis of factors linked to 
SICH, but have previously looked at SICH prediction scores 
in our population.27 In a large case series, prophylactic 
low molecular weight heparin was not associated with an 
increased risk of SICH.28 Although we do not have the data, 
it is probable that patients receiving heparin developed 
Table 2 Multivariable logistic regression analysis of (i) independent survival and (ii) mortality at three months
Outcome
3-month death or dependency (mRS ≥3) 3-month mortality
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age ≥80 2.73 1.73-4.31 <0.001 2.34 1.46-3.74 <0.001
Male sex 1.11 0.78-1.60 0.56 1.32 0.87-2.00 0.19
Pre-stroke dependency 7.79 2.60-23.3 <0.001 3.75 1.97-7.15 <0.001
Previous stroke or TIA 1.03 0.64-1.64 0.91 1.06 0.64-1.75 0.83
Hypertension 1.08 0.71-1.65 0.71 1.02 0.65-1.62 0.92
Diabetes 0.78 0.47-1.29 0.33 0.97 0.55-1.68 0.90
Atrial fi brillation 1.31 0.84-2.06 0.23 1.34 0.85-2.11 0.21
Congestive cardiac failure 16.7 3.16-88.2 0.001 3.56 1.4-9.0 0.007
Prior antiplatelet use 1.22 0.81-1.82 0.34 1.22 0.78-1.92 0.39
Prior anticoagulant use 0.74 0.43-1.27 0.28 1.15 0.65-2.04 0.63
Prior antihypertensive use 1.48 0.95-2.31 0.09 1.47 0.89-2.41 0.13
Smoking
   Ex vs. never













Baseline NIHSS 1.18 1.15-1.21 <0.001 1.16 1.13-1.19 <0.001
Systolic blood pressure 
(10mmHg rise)
1.00 0.91-1.10 0.98 0.96 0.88-1.06 0.47
Onset to needle time 
(10-minute increase)
1.00 0.98-1.02 0.75 1.01 0.99-1.03 0.34
Disappearance of hyperdense 
artery sign
   All patients
   In patients <80a








aAn interaction between age group and disappearance of hyperdense artery sign was included in the model of death or dependency at 
three months. NIHSS: National Institutes of Health stroke scale
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stroke in hospital and were receiving thromboprophylaxis, 
and therefore more medically complex. Predictive models of 
those at highest risk of SICH are only modestly accurate and 
demonstrate patients at highest risk of SICH are still likely 
to benefi t from thrombolysis, so that estimated SICH risk is 
not a reason to withhold thrombolysis.25
In AIS patients, pre-stroke dependency was associated 
with nearly four fold increased odds of mortality, with high 
mortality rates whether aged ≥80 (57%), or <80 years (71%). 
More randomised controlled trials including patients with 
pre-stroke dependency (mRS ≥3) may be required to justify 
treating this subset of patients. At the very least these data 
highlight uncertainty of the benefi ts and risks of off label 
use of thrombolysis in this group and the importance of 
discussing poor prognosis when consenting patients or next 
of kin for thrombolysis. A study of over 7,000 thrombolysed 
AIS patients found an mRS ≥3 rate of 6.6%26 which was 
associated with increased mortality (adjusted OR 2.19), 
but no increased SICH rate (4.8% vs. 4.5%). The authors 
concluded withholding thrombolysis from patients with pre-
stroke dependency may not be justifi ed.
The main strengths of this study are its prospective data 
collection, a representative patient sample (we sought to 
include all patients in the hospital who received thrombolysis 
for stroke), and relatively large sample size. This study also 
has several limitations. It is a case series, not a randomised 
trial, therefore confounding and bias may affect comparisons 
between groups. The main analyses are from a single centre 
so may not be generalisable to all other centres, although 
the data we compared with UK and world centres paralleled 
the trends we observed. We did not compare outcomes 
in those without thrombolysis so cannot comment on the 
relative effectiveness of thrombolysis in our patient group. 
The outcomes observed in this study do not cover all aspects 
of life following a stroke. Our data defi ned dependency based 
on mRS≥3 but did not contain an index of frailty or cognitive 
status, both variables which may infl uence outcome and any 
benefi t from stroke thrombolysis.
The data from this study question the appropriateness of 
treating stroke patients with pre-existing dependency given 
the very poor outcomes, regardless of age. These data may 
help inform discussions with patients and relatives when 
considering thrombolysis. The research evidence clearly 
endorses thrombolytic treatment in the over 80s who were 
previously independent within three hours of symptom onset, 
and probably within four and a half hours of symptom onset;9 
however outside these limits uncertainty and debate exists 
and further randomised trials would inform practice as 
previously suggested.26 Identifi cation of factors that predict 
response to treatment would be helpful in patient selection, 
and patients with extensive clot burden may be more likely 
to benefi t from clot retrieval. 
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